Credit: Adobestock.com
UK approval for Eylea biosimilar. Biotechnology company Formycon recently announced Medicines and Healthcare products Regulatory Agency (MHRA) approval for FYB203 (aflibercept), its Eylea biosimilar. Trading under the brand name AHZANTIVE, the therapy will be made available in the UK for the treatment of nAMD, as well as other serious retinal conditions including macular edema following retinal vein occlusion (RVO) and diabetic macular edema (DME). Link
Dry eye drop from Alcon. Last week, Alcon announced the US launch of its latest over-the-counter dry eye drop, SYSTANE PRO Preservative-Free (PF). Chief Medical Officer and Head of Global Medical Safety at Alcon, Terry Kim, stated that SYSTANE PRO PF is “the first and only multi-dose preservative-free triple action formula with hyaluronate, nano-sized lipids and HP-Guar that support the active ingredient giving patients long-lasting relief from the symptoms of dry eye.” Link
Interventional glaucoma consensus. A US-based team of researchers have reviewed evidence in favor of the "interventional glaucoma (IG) revolution” to propose a protocol that might be used as a practical guide for surgeons “seeking to incorporate IG principles into their practices.” The study outlined individual protocols for each stage of the disease with the aim of enhancing glaucoma patient outcomes, improving adherence, and reducing reliance on topical medication. Link
Early Alzheimer’s biomarker. Researchers from the Indiana University School of Medicine have examined retinal dysfunction in a humanized APOE4 knock-in (KI) mouse model of Alzheimer's disease (AD). Their findings reveal that APOE4-KI mice exhibit structural and functional retinal impairments, including reduced retinal thickness, vascular abnormalities, neuroinflammation, and decreased visual acuity and contrast sensitivity. Link
Ocular Pain Assessment. Employing Rasch analysis, a TVST study has sought to evaluate the psychometric properties of the Ocular Pain Assessment Survey (OPAS) in an Asian population with dry eye disease (DED) and neuropathic corneal pain (NCP). The study identified both strengths and weaknesses in the OPAS questionnaire, and the authors emphasize the need for refinement in pain assessment tools to enhance their effectiveness in real-world clinical settings. Link
